Lower Risk of Cancer in Patients on Metformin in ComparisonWith Those on Sulfonylurea Derivatives Results from a large population-based follow-up study

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals

  2011cited by this paper
• Potential programming of dopaminergic circuits by early life stress

  2011cited by this paper
• Metformin: taking away the candy for cancer?

  2010cited by this paper
• Metformin and Cancer Occurrence in Insulin-Treated Type 2 Diabetic Patients

  2010cited by this paper
• Diabetes therapy and cancer risk: causal effects and other plausible explanations

  2010cited by this paper
• Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies

  2010cited by this paper
• Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis

  2010cited by this paper
• Diabetes, Insulin Use, and Cancer Risk: Are Observational Studies Part of the Solution–or Part of the Problem?

  2010cited by this paper
• Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure

  2010cited by this paper
• Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease

  2010cited by this paper
• Insulin Glargine and Cancer Risk: An Opinion Statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy

  2010cited by this paper
• Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma

  2010cited by this paper
• Diabetes and Cancer

  2010cited by this paper
• The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

  2009cited by this paper
• Metformin use and prostate cancer in Caucasian men: results from a population-based case–control study

  2009cited by this paper
• New Users of Metformin Are at Low Risk of Incident Cancer

  2009cited by this paper
• Diabetes treatment with insulin glargine and risk of malignancy: methodological pitfalls and ethical issues

  2009cited by this paper
• Antidiabetic therapies affect risk of pancreatic cancer.

  2009cited by this paper
• Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy

  2009cited by this paper
• Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies

  2008cited by this paper
• Sulphonylureas and cancer: a case–control study

  2008cited by this paper
• Metformin and reduced risk of cancer in diabetic patients

  2005cited by this paper
• Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients.

  2004cited by this paper

• Obesity, metformin prescription and risk of advanced prostate cancer in non-diabetic men

  2026cites this paper
• Association of metformin use with risk and survival outcome of esophageal cancer in patients with diabetes: A systematic review and meta-analysis

  2025cites this paper
• Diabetes and the risk of bladder cancer subtypes in men and women: results from the Netherlands Cohort Study

  2024cites this paper
• Comparing the effects of biguanides and dipeptidyl peptidase-4 inhibitors on cardio-cerebrovascular outcomes, nephropathy, retinopathy, neuropathy, and treatment costs in diabetic patients

  2024cites this paper
• Does metformin really reduce prostate cancer risk: an up-to-date comprehensive genome-wide analysis

  2024cites this paper
• Metformin and other anti‐diabetic medication use and breast cancer incidence in the Nurses' Health Studies

  2024cites this paper
• The relationship between the use of metformin and the risk of pancreatic cancer in patients with diabetes: a systematic review and meta-analysis

  2023cites this paper
• Influence of diabetes mellitus and effectiveness of metformin on hepatocellular carcinoma

  2023cites this paper
• Targeting lipid metabolism in metastatic prostate cancer

  2023cites this paper
• Threat of Prostate Cancer by Diabetes: The Combination effects of Metformin and Sulfonylurea

  2023cites this paper
• The Association of Long-Term Metformin Use with Cancer Risk in Type 2 Diabetes: A Systematic Review of the Evidence and Methodological Controversies

  2023cites this paper
• Metformin Use May Increase Risk of Pancreatic Cancer in Diabetic Women: An Analysis of the Korean National Health Insurance Service-National Health Screening Cohort Database

  2022cites this paper
• Breast cancer risk for women with diabetes and the impact of metformin: A meta‐analysis

  2022cites this paper
• The role of AMPK-dependent pathways in cellular and molecular mechanisms of metformin: a new perspective for treatment and prevention of diseases

  2022cites this paper
• Aspirin, metformin, and statin use on the risk of gastric cancer: A nationwide population‐based cohort study in Korea with systematic review and meta‐analysis

  2021cites this paper
• EliScholar – A Digital Platform for Scholarly Publishing at Yale

  2021influential citation
• Is metformin use associated with a reduced risk of oesophageal cancer? A systematic review and meta-analysis

  2021cites this paper
• Association between metformin medication, genetic variation and prostate cancer risk

  2020cites this paper
• The quest to slow ageing through drug discovery

  2020cites this paper
• Repurposing old drugs to fight multidrug resistant cancers.

  2020cites this paper
• The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances

  2019cites this paper
• Metformin-activated AMPK regulates β-catenin to reduce cell proliferation in colon carcinoma RKO cells

  2019cites this paper
• CDX1 Expression Induced by CagA-Expressing Helicobacter pylori Promotes Gastric Tumorigenesis

  2019cites this paper
• Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial

  2019cites this paper
• Clinical Autonomic and Mitochondrial Disorders: Diagnosis, Prevention, and Treatment for Mind-Body Wellness

  2019cites this paper
• Metformin use and prostate cancer risk

  2019cites this paper
• Metformin use and risk of gastric adenocarcinoma in a Swedish population-based cohort study

  2019cites this paper
• Impact of oral hypoglycemic agents on mortality among diabetic patients with non-muscle-invasive bladder cancer: A populationbased analysis.

  2018cites this paper
• A Trusted Healthcare Data Analytics Cloud Platform

  2018cites this paper
• The investigation of the effects of Metformin in Thyroid Cancer

  2018influential citation
• Systematic review and meta-analysis of the effect of metformin treatment on overall mortality rates in women with endometrial cancer and type 2 diabetes mellitus.

  2017cites this paper
• Exploiting Electronic Health Records to Mine Drug Effects on Laboratory Test Results

  2017cites this paper
• Association between light at night, melatonin secretion, sleep deprivation, and the internal clock: Health impacts and mechanisms of circadian disruption

  2017cites this paper
• Use of statins offsets insulin‐related cancer risk

  2017cites this paper
• Metformin and cancer in type 2 diabetes: a systematic review and comprehensive bias evaluation

  2017cites this paper
• From obesity to diabetes and cancer: epidemiological links and role of therapies

  2016cites this paper
• Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study

  2016cites this paper
• Statins and metformin for chemoprevention of hepatocellular carcinoma

  2016cites this paper
• Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular Carcinoma

  2016cites this paper
• Metformin and cancer in type 2 diabetes: a systematic review and comprehensive bias evaluation

  2016cites this paper
• Regulation of prostate cancer cell function by activators of AMP-activated protein kinase

  2016cites this paper
• High efficacy of intravesical treatment of metformin on bladder cancer in preclinical model

  2016cites this paper
• A study of the descriptive epidemiology and clinical effectiveness of treatment for type 2 diabetes using routine general practice data

  2015cites this paper
• Type 2 Diabetes and Breast Cancer: The Interplay between Impaired Glucose Metabolism and Oxidant Stress

  2015cites this paper
• When Anti-Aging Studies Meet Cancer Chemoprevention: Can Anti-Aging Agent Kill Two Birds with One Blow?

  2015cites this paper
• The Use of Glyburide Compared With Other Sulfonylureas and the Risk of Cancer in Patients With Type 2 Diabetes

  2015cites this paper
• Metformin therapy and prostate cancer risk: a meta-analysis of observational studies.

  2015influential citation
• Metformin and breast and gynecological cancer risk among women with diabetes

  2015cites this paper
• The Anticancer Effect of Metformin, the Most Commonly Used Anti-Diabetes Drug

  2014cites this paper
• Metformin and Pancreatic Cancer Metabolism

  2014influential citation
• Chemopreventive strategies in hepatocellular carcinoma

  2014cites this paper
• Systematic Reviews and Meta- and Pooled Analyses Reduced Risk of Lung Cancer With Metformin Therapy in Diabetic Patients: A Systematic Review and Meta-Analysis

  2014influential citation
• Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.

  2014cites this paper
• Metformin in cancer prevention and therapy.

  2014cites this paper
• Metformin Sensitizes EGFR-TKI–Resistant Human Lung Cancer Cells In Vitro and In Vivo through Inhibition of IL-6 Signaling and EMT Reversal

  2014cites this paper
• Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-analysis Taking into Account Biases and Confounders

  2014cites this paper
• Effect of metformin on prostate cancer outcomes after radical prostatectomy.

  2014cites this paper
• Anti-diabetic medications and risk of primary liver cancer in persons with type II diabetes

  2014cites this paper
• DIABETIC STUDIES The Review of Metformin and Cancer

  2014cites this paper
• Association of metformin use with cancer incidence and mortality: a meta-analysis.

  2013cites this paper
• Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis

  2013cites this paper
• Risk vs Benefit in Diabetes Pharmacotherapy: a Rational Approach to Choosing Pharmacotherapy in Type 2 Diabetes

  2013cites this paper
• Diabets and the incidence of cancer in a Portuguese urban cohort

  2013cites this paper
• Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review

  2013influential citation
• The IRS1 rs2943641 variant and risk of future cancer among morbidly obese individuals.

  2013cites this paper
• Antidiabetic Medications and the Risk of Colorectal Cancer in Patients with Diabetes Mellitus: A Systematic Review and Meta-analysis

  2013cites this paper
• Risk of Cancer in Diabetes: The Effect of Metformin

  2013cites this paper
• Management of type-2 diabetes mellitus in adults: focus on individualizing non-insulin therapies.

  2012cites this paper
• Erratum to: Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials

  2012cites this paper
• Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials

  2012cites this paper